Clinical trials: Carcinoma of Lung
Lung Cancer
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
- Trial name
- BECOME (NCT05055908)
- Testing
- Pemetrexed plus Pembrolizumab, Pembrolizumab, Pemetrexed
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Hunan Province Tumor Hospital
The Efficacy and Safety of SBRT in MPLC
The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)
To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary…
- Trial name
- SMILE (NCT05113017)
- Testing
- NO Intervention
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Fang Wu
Small Cell Lung Cancer
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
This study is aimed to evaluate the progression-free survival(PFS) and also survival of IP and EP (head-to-head) as the first line therapy for extensive stage small-cell lung cancer and to explore the reasonable first-line…
- Trial name
- NCT02348450
- Testing
- Irinotecan, Etoposide, Cisplatin
- Where
- 20 sites in China
- Volunteers
- 308 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-small Cell Lung Cancer
Circulating DNA in Surgically Treated NSCLC
The investigators will prospectively recruit 100 NSCLC patients. The cfDNA samples will be gathered before the surgery and postoperatively 4-6 weeks after surgery and at 6 and 12 months follow-up visits.
- Trial name
- NCT04037150
- Testing
- Circulating tumor DNA
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Lung Cancer
A Feasibility Study of Unsupervised, Pre-operative Exercise Program for Patients Scheduled for Lung Cancer Surgery
The paradigm of pre-operative exercise as a neoadjuvant therapy to reduce morbidity is increasingly promoted within general surgery and surgical oncology.
- Trial name
- NCT03162718
- Testing
- Exercise
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Lung Cancer
Precision Diagnosis and Therapy for Early Stage Lung Cancer
The present study is a single arm clinical trial aiming to improve the key technology in the diagnosis and treatment of early stage lung cancer.
- Trial name
- NCT02936804
- Testing
- Low Dose Computed Tomography
- Where
- China
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer
Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial
Concurrent chemoradiotherapy is the standard treatment for locally advanced, unresectable non-small cell lung cancer, but carries a risk of radiation pneumonitis of approximately 30%, and is associated with a decline in pulmonary…
- Trial name
- FLAIR (NCT02002052)
- Testing
- Concurrent platinum-based chemotherapy, Standard Radiotherapy, 60 Gy in 30 fractions., Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Squamous Cell Lung Cancer
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib.
- Trial name
- ECLIPSE (NCT01082549)
- Testing
- gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
- Where
- 142 sites in United States, Belgium and 12 more
- Volunteers
- 780 people
- Sponsor
- Sanofi
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of onalespib lactate when given together with erlotinib hydrochloride and to see how well they work in treating patients with EGFR-mutant non-small cell lung cancer…
- Trial name
- NCT02535338
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Onalespib Lactate
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00004176
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Obstructive Sleep Apnea, Non-small Cell Lung Cancer
Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer
This prospective, observational cohort study aims to explore the influence of obstructive sleep apnea(OSA) on the efficacy of PD-1-based immunotherapy in patients with non-small cell lung cancer(NSCLC).
- Trial name
- NCT04743752
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Adenocarcinoma
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik.
- Trial name
- NIRPA (NCT03695835)
- Testing
- Immunotherapeutic Agents, Ablation
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Gary Onik MD
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl.
- Trial name
- NAUTIC (NCT06494540)
- Where
- 30 sites in Germany
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
- Trial name
- ATHENA (NCT04322617)
- Testing
- Anlotinib plus the same Immune Checkpoint Inhibitors., Anlotinib plus the new Immune Checkpoint Inhibitors., Anlotinib
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Hunan Province Tumor Hospital
Mesotheliomas Pleural
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
This is a multicentric double-blind, placebo controlled, phase III trial. In this study, patients who underwent to a surgical resection of pleural mesothelioma and are without signs of macroscopic residual disease will be…
- Trial name
- AtezoMeso (NCT04996017)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection
- Where
- 19 sites in Italy
- Volunteers
- 162 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Lung Cancer
Prediction of Esophageal and Lung Toxicities After Radiation (Chemo) Therapy
(Chemo)-radiotherapy is the gold standard therapeutic treatment for patients with locally advanced lung cancer non accessible or ineligible for surgery.
- Trial name
- PTOP-RT (NCT04545658)
- Where
- France
- Volunteers
- 167 people
- Sponsor
- University Hospital, Brest
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
This phase II trial studies how well danvatirsen and durvalumab work in treating patients with pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency
- Trial name
- NCT02983578
- Testing
- Danvatirsen, Durvalumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003089
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.